Cryopreservation and thawing of haematopoietic stem cells are associated with cell loss and infusion-related toxicities. We analysed viability, total nucleated cell (TNC) and CD34 þ cell recovery, and infusion-related toxicities of 952 thawed and washed products. Mean TNC and CD34 þ viable cells recoveries were 55.9718.6 and 98.0736.5%, respectively. Mean cell viability was 68.25718.9%. TNC recovery was correlated with viability but independent of the initial nucleated cell concentration. No difference in TNC recovery or viability was observed according to underlying diseases, except for myeloma, for which these variables were significantly lower (Po0.05). CD34 þ cell recovery was not correlated with viability or CD34 þ initial count and was similar for all diseases. Cryostorage duration was not associated with cell loss. Immediate adverse events occurred in 169 patients (19%) and were moderate (grade I or II) for the majority of patients. Clinical toxicity was associated with a higher infused cell number and the presence of clumps in infused bags. The washing procedure of cell products lead to a low rate of adverse events, but patients transplanted with high cell numbers or bags in which clumps were identified are predisposed to such complications.
Introduction
Over the last decade, the clinical applications of autologous haematopoietic stem cell transplantation have considerably increased. Haematopoietic stem cell transplantation is still mainly used for the treatment of haematological malignancies, but also in other disorders such as solid cancers. 1 Autologous haematopoietic progenitor cells (HPC) can be collected from either peripheral blood after mobilization by growth factors following or not chemotherapy, or from bone marrow, the majority of patients receiving cryopreserved peripheral blood HPC. The major concern for cell preservation resides in the freezing step that can damage cells and thus requires the addition of cryoprotectants in order to optimize cell viability and function at the time of thawing. 2 HPC are usually frozen in autologous plasma or macromolecules in solution with a final concentration of 10% dimethylsulphoxide (DMSO) and then stored in liquid or gas-phase nitrogen until reinfusion. 3, 4 In spite of these precautions, cryopreservation is associated with variable loss of cell viability and a reduction in the absolute number of viable CD34 þ cells available for reinfusion. [5] [6] [7] It has been related to the direct effect of low temperature and the formation of ice crystals, 8 or to DMSO only. 9 Infusion of thawed products may induce a wide variety of adverse events usually mild to moderate. The most frequent adverse events reported in the literature include nausea, vomiting, hypo or hypertension and bradycardia. Headache, abdominal cramps, diarrhoea, flushing, chills, fever and chest tightness have also been described. [10] [11] [12] Severe reactions, such as life threatening cardiologic, neurologic, pulmonary, anaphylactic and renal events [13] [14] [15] [16] [17] [18] are considered to be rare events.
These complications have mainly been related to DMSO, 10, 19 damaged cells and lysis products 20 or free haemoglobin and red blood cell content.
In this report, we retrospectively analyse cell recoveries and viability of 952 thawed and washed HPC grafts obtained from 886 patients, and identify parameters associated with clinical toxicity at the time of graft infusion.
Materials and methods

Patients
Nine hundred and fifty-two peripheral blood progenitor cell components were collected from 886 patients with the following diagnoses: solid cancers (n ¼ 236), non-Hodgkin lymphomas (n ¼ 226), Hodgkin lymphoma (n ¼ 84), multiple myeloma (n ¼ 270) and other haematological diseases (acute and chronic leukaemia, n ¼ 70), between 1999 and 2004.
The peripheral blood progenitor cells were harvested by apheresis after mobilization with either glycosylated recombinant human granulocyte colony-stimulating factor alone or following various chemotherapy regimens, administered subcutaneously at a single daily dose of 5 mg kg À1 for 4-6 days. The collection process started on the fifth day of recombinant human granulocyte colony-stimulating factor administration or during the haematologic recovery after chemotherapy and recombinant human granulocyte colony-stimulating factor, if at least 10 CD34 þ cells per microlitre were present in the peripheral blood sample. Haematopoietic stem cells were collected on a continuousflow blood cell separator (COBE spectra cell separator, Gambro BCT, Lakewood, CO, USA). A median number of three times the patient's blood volume was processed each time. A minimum of 3 Â 10 6 CD34 þ cells per kilogram of patient weight and per graft was collected. Consent was obtained prior to the procedure from all patients following institutional guidelines.
Cryopreservation Peripheral blood progenitor cell products were either processed immediately after collection or stored overnight at 41C.
For security reasons, the leucapheresis components were cryopreserved in at least two freezing bags (Baxter, Maurepas, France), in a final nucleated cells (NC) concentration per bag equal to or lower than 3 Â 10 8 NCs per millilitre Samples for cell count, viability and bacteriological control assessment were taken before cryopreservation and after the washing step of the thawing procedure. For microbial culture, 1 ml of graft sample was inoculated into a blood culture flask from a commercial source in both aerobic and anaerobic conditions (Bact/Alert SA and SN, Biome´rieux, Marcy l'Etoile, France). Samples were incubated for 14 days at 371C. The cryoprotectant solution was composed of voluven (Fresenius Kabi, Sevres, France) and DMSO (B Braun, Boulogne, France). The volume of the cryoprotectant solution was calculated to obtain a final volume of 140 ml per bag and the quantity of DMSO was calculated to achieve a DMSO final concentration of 10% (vol/vol). The cryoprotectant solution was chilled to 41C and added to the cells in freezing bags. The bags were transferred to a controlled freezer (NICOOL, Airliquide, France), cooled at 1.61C per minute to À401C, and at 91C per minute to À1201C, and then stored in gas-phase nitrogen until reinfusion.
Although it has been shown that haematopoietic stem cells may retain engraftment capacity after extended cryostorage, 21 the effect of storage duration on cell recovery and viability was analysed in two groups as follows: one transplanted with cells cryopreserved for less than 4 months and another for more than 4 months.
Thawing, washing and infusion Immediately after removal from nitrogen tanks, frozen bags were thawed in a 371C water bath. The bag was removed from the water bath when only an ice cube remained visible and the cell suspension obtained was immediately diluted with a saline solution with 10% acid citrate dextrose anticoagulant (ACD; MacoPharma, Tourcoing, France) to a final volume of 600 ml. For washing, the bag was adapted on a COBE 2991 cell washer and the cell suspension centrifuged at 1850 r.p.m. for 6 min. At the end of this first centrifugation step, supernatant waste was removed from the cell washer by fixing the flow at 100 ml min À1 . The remaining cell suspension was automatically agitated for 80 s. Saline/acid citrate dextrose solution was added again and the washing process was repeated twice when only one bag had to be thawed, or three times if two bags were thawed. The cell product was then gently diluted in a glucose 5% solution, filtered and adjusted to a final infused volume of about 200 ml. Samples were taken for cell count, viability and bacteriological control assessment. The graft infusion was performed through a standard 170-mm blood filter in order to remove macroscopic clumps before infusion. The presence of macroscopic clumps in the graft was recorded both by the technicians at the end of the thawing and washing procedures, and the physicians before transplantation. Cell suspensions were infused into the patient through a central venous catheter in 45 min to 1 h.
Cell count
Nucleated cells from leucapheresis products and thawed bags were counted on an automated cell counter (Sysmex, Roche Diagnostics, Meylan, France).
The proportions of mononuclear cells and CD34 þ cells were identified by flow cytometry.
Briefly, 1 Â 10 6 cells were incubated with anti-CD34-phycoerythrin and CD45-fluorescein isothiocyanate-conjugated monoclonal antibodies (all purchased from Becton Dickinson, San Jose, CA, USA). After a washing step in phosphate-buffered saline, the samples were incubated for 15 min at room temperature with 1 ml of ammonium chloride solution (Ortho-mune lysing reagent, Ortho, Raritan, NJ, USA), washed again and then acquired on a flow cytometer (FACS calibur with Cell Quest software, Becton Dickinson). A unique gate based on CD34 staining of low side-scatter events was performed to identify the CD34 þ cell population. The mononuclear cells were identified by flow cytometry as low and intermediate sidescatter events, which include lymphocytes, monocytes and early progenitors. Cell viability was assessed by propidium iodide using a flow cytometric procedure. Cell recoveries, expressed as percentages, were calculated according to cell count obtained before freezing and after the thawing procedure as follows: (cell number after thawing/cell number before freezing) Â 100. CD34 þ counts were expressed as the number of viable CD34 þ cells after thawing.
Adverse events
Infusion-related toxicities were collected during the first transplantation for the 886 patients. These included hyperthermia, erythema, headache, nausea, vomiting, abdominal pain, diarrhoea, blood pressure modification, pulse modification, dyspnoea and seizure. Adverse events were graded according to the WHO (World Health Organization) classification.
Statistical analysis
Regression analysis and coefficient of correlation (r 2 ) measurement were used to compare the cell recovery data. Differences between the results of comparative tests were considered significant if the two-sided P-value was less than 0.05. All statistical analyses were performed using the SAS 9.1 software (SAS Institute, Cary, NC, USA).
Results
Cell recovery and viability
Total nucleated cell recovery and the cell viability were 55.9718.6 % (range 11-200) and 68.25718.9% (range 15-99), respectively. As expected, total NC recovery (TNCR) strongly correlated with viability (r 2 ¼ 0.66, Po10
À4
; Figure 1a ) and inversely correlated, as cell viability, with the granulocytic cell concentration before cryopreservation (r 2 ¼ 0.43, Po10
; Figure 1b) . Conversely, TNCR and the viability after thawing were neither linked with the TNC count before cryopreservation, nor to the concentration of TNCs frozen per millilitre (not shown). We next addressed the question of whether or not the initial diagnosis influenced the TNCR at the time of graft thawing. Whereas no differences for TNCR and viability were observed for patients with solid cancers, for Hodgkin lymphoma, nonHodgkin lymphomas or various haematological diseases (P40.05 for each group comparison), a slight but significant (Po0.05) decrease in cell viability was observed for patients with myeloma (Table 1) . These results were independent of the initial TNC count or TNC concentration per frozen bag, thus suggesting that TNCs from myeloma patients were less resistant to the thawing procedure.
We next analysed the relationship between storage duration, TNCR and viability in all grafts. The majority of graft products were thawed during the first 4 months following apheresis (n ¼ 826, 82.1%). One hundred and eighty products (17.9%) were thawed more than 4 months after cryopreservation, with a maximum period of 111 months. TNCR and viability were found to be similar in these two statistically comparable groups (55.9 versus 54.6%, and 68.3 versus 67.6%, respectively), thus confirming that long-term storage did not seem to profoundly affect cell recovery (not shown).
We next analysed similar parameters regarding the CD34 þ haematopoietic stem cells. Mean CD34 þ cell recovery was found to be 98.0736.5% (range 12-252). We could neither find correlation between CD34 þ cell recovery and viability, nor between haematopoietic progenitor cell recovery and initial CD34 þ cell count or concentration at the time of freezing (not shown). Moreover, CD34 þ cell recovery was not correlated with granulocytic cell concentration. In addition, CD34 þ cell recovery was independent of the initial diagnosis, with comparison between TNCR and granulocytic cells concentration. TNCR, total nucleated cell recovery. The microbial analysis of the 952 HPC products revealed that none of them were contaminated at the time of harvest or after the thawing and washing procedures.
Adverse events
One hundred and sixty-nine patients out of 886 (19%) displayed one or more adverse event associated with their graft infusion. Among these, 110 (65%) had only one, 44 (26%) experienced two, four (2.4%) had three and eight (4.7%) had more than three (Figure 2) . In almost all of the patients experiencing infusion-related complications, these were of grade pII as defined by the WHO classification, rapidly resolving after graft infusion and were mainly nausea, headaches, vomiting, erythema or transient abdominal pain. Three patients however experienced severe adverse events (seizures) and two of them needed intensive care. All had a favourable outcome. There was no difference in the occurrence of adverse events according to underlying disease.
We did not observe any correlation between TNC or CD34 þ cell recovery and the occurrence of clinical complications, even if slightly less infusion-related toxicities were observed for patients with highest TNCR (not shown).
Interestingly, we observed that 9% of patients receiving a TNC-infused dose of 15 Â 10 9 or less cells experienced a post transplant adverse event and this percentage rose to 31% for patients receiving 42 Â 10 9 or more TNCs (Po0.05). Thus, there were more clinical complications when a higher number of cells were infused. This was not related to the infused volume, which did not differ significantly from one bag to another (approximately 200 ml).
Finally, we analysed the clinical impact of the presence of clumps in the graft product. The analysis was based on data recording for each patient the presence or the absence of macroscopic clumps in cell suspension by visual examination, at the time of infusion. We found that patients receiving grafts in which clumps were observed experienced significantly more adverse events than those transplanted with products without clumps (42 versus 13%, Po0.05). These data suggest that clumps might represent a marker of risk for developing adverse events during transplantation. The presence of clumps was not associated with TNCR, CD34 þ cell recovery or viability (not shown).
Discussion
In this study, we showed that TNCR was correlated with viability, as expected, and that TNCR and cell viability were inversely correlated with the concentration of granulocytic cells. CD34 þ cell recovery was neither linked with viability nor with granulocyte concentration. This might be because the tolerance of granulocytes to DMSO is lower than that of lymphocytes or immature HPCs. 22 Cell count and concentration at freezing were not predictive of cell recovery after thawing, as previously shown for both bone marrow and peripheral blood stem cell products. 23 Moreover, the NC and CD34 þ cell recovery and the viability were not linked with the duration of freezing in this study, consistent with data showing that HSC retain engraftment potential after extended (5-14 years) cryostorage. 21, 24, 25 Interestingly, we found a significant decrease in NC recovery and viability in patients with myeloma. It could be related to the higher granulocyte count in the apheresis collection in myeloma than in other patients (48 versus 40%, P ¼ 0.0001). It may also be hypothesized that monoclonal immunoglobulin reduces NC recovery and viability by facilitating mature cell aggregation, activation and death. On the other hand, no statistically significant difference were observed for the CD34 þ cell recovery according to disease, as previously shown. 6 We also evaluated the type and the occurrence of adverse events during cell infusion. A wide variety of complications, usually mild to moderate, have already been described in patients receiving thawed but non-washed products, and include nausea, vomiting, hypotension and rare lifethreatening cardiologic or renal events. 12 The incidence of these events was variable and ranged from 8 11 to 45% 10 for non-cardiovascular complications. Cardiovascular events, such as hypertension, arrhythmias or heart blocks occurred in 41, 82 and 24% of cases, respectively for some authors. 26 Others found 36% of hypertension, and in the same study, only two patients out of 75 experienced bradyarrythmia. 11 Since complications have been mainly related to DMSO, we decided to wash all the cryopreserved products. This is of particular interest for patients transplanted with grafts cryopreserved in 3 or 4 bags, for which the total amount of DMSO is 45-60 ml. Moreover, we did not observe any impact of this process on haematopoietic recovery compared with products thawed at the bedside. In our study, the majority of patients did not experienced clinical toxicity during reinfusion (81%). This observed low rate of adverse events may be due to the reduction of DMSO in the infused bags obtained by washing cells before infusion, as previously shown. 27, 28 Adverse events have also been related to cell lysis products. 12 In our report, more adverse events occurred Patients (n) Figure 2 Immediate adverse events reported after graft infusion.
Recovery and clinical toxicity of thawed PBPC E Foïs et al when a higher number of cells was transplanted and we thus recommend that where there is a very high number of cells to be infused, that at least two aliquots be prepared and infused separately. In addition, we observed more infusion-related toxicities when infused bags contained clumps at thawing, even if a standard 170-mm blood filter was used during infusion. The cell concentration tended to be higher in bags with clumps (data not shown), while the difference did not reach statistical significance. We wondered whether clumps, resulting from cell aggregation, could induce the release cytokines, which might be responsible for systemic effects in patients during infusion. This may explain the higher incidence of adverse events in patients receiving higher cell concentrations or grafts in which clumps were observed.
In conclusion, we found a correlation between granulocyte concentration and total NC recovery, but not with CD34 þ cell recovery. We showed that cell washing after thawing lead to a low rate of immediate adverse events after graft infusion and that clinical toxicity was in our hands, related to high infused cell concentration and to the presence of clumps, two variables that correlated with each other.
